Granules India, a pharmaceutical company across the whole value chain, has received a VIA (voluntary action indicated) FDA notification, for Granules Life Sciences.
Headquartered in Hyderabad, the Life Sciences division is based in Shamirpet, Telangana.
No regulatory action has been recommended, according to a company statement.
Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India Limited, said “While receiving the classification is a step in the right direction, we recognize that quality is not a one-time milestone but an ongoing commitment. It will continue to remain a core pillar of utmost importance across all Granules sites, guiding our actions, investments, and culture every day.”
